Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
24.65
+1.13 (4.80%)
At close: Jan 23, 2025, 4:00 PM
24.87
+0.22 (0.91%)
After-hours: Jan 23, 2025, 7:58 PM EST
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
18.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
| Dec 31, 2019 | 810.55K | -56.28M | -98.58% |
| Jan 31, 2019 | Pro | Pro | Pro |
| Jan 31, 2018 | Pro | Pro | Pro |
| Jan 31, 2017 | Pro | Pro | Pro |
| Jan 31, 2016 | Pro | Pro | Pro |
| Jan 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
SMMT News
- 5 days ago - Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
- 7 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 16 days ago - Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 21 days ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 7 weeks ago - Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha
- 2 months ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga